On August 31, 2026, the Trump administration announced agreements with nine midsize pharmaceutical companies to provide most-favored-nation prices to state Medicaid programs and lowest global prices for new U.S. medications. These firms join 17 larger companies that signed earlier deals, bringing the total to 26 companies representing 90% of the domestic market. The administration projects more than $600 billion in savings and reports $19.6 billion in manufacturing commitments alongside recent price declines.